ArticleJTO clinical and research reports2021

Phase 2 Study of YS110, a Recombinant Humanized Anti-CD26 Monoclonal Antibody, in Japanese Patients With Advanced Malignant Pleural Mesothelioma.

Kazuhiko Nakagawa et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.